These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

130 related items for PubMed ID: 1422477

  • 1. Fractionated TBI and methotrexate-cyclosporin do not seem to increase relapses in BMT for first chronic phase CML patients: results of a single centre study.
    López J, Vázquez L, Serrano F, Kassack JJ, Figuera A, Steegmann JL, Cámara R, Lamana M, Ferro T, Fernández-Villalta MJ.
    Bone Marrow Transplant; 1992 Sep; 10(3):235-9. PubMed ID: 1422477
    [Abstract] [Full Text] [Related]

  • 2. Prognostic factors for long-term survival in leukemic marrow recipients with special emphasis on age and prophylaxis for graft-versus-host disease.
    Aschan J, Ringdén O.
    Clin Transplant; 1994 Jun; 8(3 Pt 1):258-70. PubMed ID: 8061365
    [Abstract] [Full Text] [Related]

  • 3. Methotrexate vs Cyclosporin A as a single agent for graft-versus-host disease prophylaxis in pediatric patients with hematological malignancies undergoing allogeneic bone marrow transplantation from HLA-identical siblings: a single-center analysis in Japan.
    Koga Y, Nagatoshi Y, Kawano Y, Okamura J.
    Bone Marrow Transplant; 2003 Jul; 32(2):171-6. PubMed ID: 12838282
    [Abstract] [Full Text] [Related]

  • 4. Bone marrow transplantation for chronic myeloid leukemia (CML) from unrelated and sibling donors: single center experience.
    Lamparelli T, Van Lint MT, Gualandi F, Occhini D, Barbanti M, Sacchi N, Ficai G, Ghinatti C, Ferrara GB, Delfino L, Pozzi S, Morabito A, Zikos P, Vitale V, Corvo R, Frassoni F, Bacigalupo A.
    Bone Marrow Transplant; 1997 Dec; 20(12):1057-62. PubMed ID: 9466278
    [Abstract] [Full Text] [Related]

  • 5. Total body irradiation and high-dose cyclophosphamide, BCNU and VP-16 (CBV) as a new preparatory regimen for allogeneic bone marrow transplantation in patients with advanced hematologic malignancies.
    Wu DP, Milpied N, Moreau P, Mechinaud-Lacroix F, Mahe B, Le Tortorec S, Rapp MJ, Bourdin S, Mahe JM, Harousseau JL.
    Bone Marrow Transplant; 1994 Nov; 14(5):751-7. PubMed ID: 7889008
    [Abstract] [Full Text] [Related]

  • 6. Prevention of graft-versus-host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft.
    Herrera C, Torres A, García-Castellano JM, Roman J, Martin C, Serrano J, Falcon M, Alvarez MA, Gomez P, Martinez F.
    Bone Marrow Transplant; 1999 Mar; 23(5):443-50. PubMed ID: 10100557
    [Abstract] [Full Text] [Related]

  • 7. Prognostic factors affecting leukemia relapse after allogeneic BMT conditioned with cyclophosphamide and fractionated TBI.
    Zapatero A, Martín de Vidales C, Pinar B, Rodríguez F, Marín A, Cerezo L, Domínguez P, Pérez Torrubia A.
    Bone Marrow Transplant; 1996 Sep; 18(3):591-6. PubMed ID: 8879623
    [Abstract] [Full Text] [Related]

  • 8. Allogeneic bone marrow transplantation for childhood acute lymphoblastic leukemia in second remission: factors predictive of survival, relapse and graft-versus-host disease.
    Moussalem M, Esperou Bourdeau H, Devergie A, Baruchel A, Ribaud P, Socie G, Parquet N, Traineau R, Hirsch I, Schaison G.
    Bone Marrow Transplant; 1995 Jun; 15(6):943-7. PubMed ID: 7581095
    [Abstract] [Full Text] [Related]

  • 9. Role of splenic irradiation in patients with chronic myeloid leukemia undergoing allogeneic bone marrow transplantation.
    Jabro G, Koc Y, Boyle T, Schenkein DP, Ravalese J, Wazer D, Miller KB.
    Biol Blood Marrow Transplant; 1999 Jun; 5(3):173-9. PubMed ID: 10392963
    [Abstract] [Full Text] [Related]

  • 10. Fractionated total-body irradiation, etoposide, and cyclophosphamide followed by allogeneic bone marrow transplantation for patients with high-risk or advanced-stage hematological malignancies.
    Long GD, Amylon MD, Stockerl-Goldstein KE, Negrin RS, Chao NJ, Hu WW, Nademanee AP, Snyder DS, Hoppe RT, Vora N, Wong R, Niland J, Reichardt VL, Forman SJ, Blume KG.
    Biol Blood Marrow Transplant; 1997 Dec; 3(6):324-30. PubMed ID: 9502300
    [Abstract] [Full Text] [Related]

  • 11. Long-term results of bone marrow transplantation for patients with AML, ALL and CML prepared with single dose total body irradiation of 500 cGy delivered with a high dose rate.
    Fyles GM, Messner HA, Lockwood G, Curtis JE, Rider W, Minden MD, Meharchand JM, Lipton J, Tritchler D, Van Dyk J.
    Bone Marrow Transplant; 1991 Dec; 8(6):453-63. PubMed ID: 1790425
    [Abstract] [Full Text] [Related]

  • 12. [Allogeneic bone marrow transplantation in chronic myeloid leukemia. The clinical results and risk factors in 70 patients].
    Tomás JF, Peñarrubia MJ, García JA, Figuera A, Gómez-García de Soria V, Steegmann JL, Arranz R, Cámara R, Gabriel R, Vázquez L.
    Med Clin (Barc); 1995 Nov 11; 105(16):605-11. PubMed ID: 8523939
    [Abstract] [Full Text] [Related]

  • 13. Comparison of total body irradiation vs busulfan in combination with cyclophosphamide as conditioning for unrelated stem cell transplantation in CML patients.
    Kröger N, Zabelina T, Krüger W, Renges H, Stute N, Kabisch H, Jaburg N, Löliger C, Krüll A, Zander AR.
    Bone Marrow Transplant; 2001 Feb 11; 27(4):349-54. PubMed ID: 11313663
    [Abstract] [Full Text] [Related]

  • 14. Individualized prophylaxis against graft-versus-host disease in leukemic marrow transplant recipients.
    Aschan J, Ringdén O, Andström E, Ljungman P, Lönnqvist B, Remberger M.
    Bone Marrow Transplant; 1994 Jul 11; 14(1):79-87. PubMed ID: 7951124
    [Abstract] [Full Text] [Related]

  • 15. Unrelated allogeneic bone marrow transplantation using high-dose busulfan and cyclophosphamide (BU-CY) for the preparative regimen.
    Sahebi F, Copelan E, Crilley P, Bolwell B, Avalos B, Klein J, Territo M, Gajewski J.
    Bone Marrow Transplant; 1996 May 11; 17(5):685-9. PubMed ID: 8733682
    [Abstract] [Full Text] [Related]

  • 16. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
    Mengarelli A, Iori A, Guglielmi C, Romano A, Cerretti R, Torromeo C, Micozzi A, Fenu S, Laurenti L, Donato V, De Felice L, Arcese W.
    Haematologica; 2002 Jan 11; 87(1):52-8. PubMed ID: 11801465
    [Abstract] [Full Text] [Related]

  • 17. Risk factors in bone marrow transplant recipients with leukaemia. Increased relapse risk in patients treated with ciprofloxacin for gut decontamination.
    Carlens S, Ringdén O, Aschan J, Hägglund H, Ljungman P, Mattsson J, Remberger M.
    Clin Transplant; 1998 Apr 11; 12(2):84-92. PubMed ID: 9575394
    [Abstract] [Full Text] [Related]

  • 18. [The analysis of leukemic relapse after allogeneic bone marrow transplantation].
    Yoshimura M, Yoshida H, Matsunashi T, Hidaka S, Kobayashi M, Yoshida S, Tominaga N, Tejima H, Hiraoka A, Nakamura H.
    Rinsho Ketsueki; 1991 Nov 11; 32(11):1433-8. PubMed ID: 1758050
    [Abstract] [Full Text] [Related]

  • 19. Hematopoietic growth factors after HLA-identical allogeneic bone marrow transplantation in patients treated with methotrexate-containing graft-vs.-host disease prophylaxis.
    Martin-Algarra S, Bishop MR, Tarantolo S, Cowles MK, Reed E, Anderson JR, Vose JM, Bierman P, Armitage JO, Kessinger A.
    Exp Hematol; 1995 Dec 11; 23(14):1503-8. PubMed ID: 8542938
    [Abstract] [Full Text] [Related]

  • 20. Unrelated donor bone marrow transplantation as treatment for chronic myeloid leukemia: the Spanish experience. The Chronic Myeloid Leukemia Subcommittee of the GETH. Grupo Español de Trasplante Hemopoyético.
    Carreras E, Tomás JF, Sanz G, Iriondo A, Boqué C, López J, Cabrera R, Sureda A, de Soria VG, Sierra J, Sanz MA, Torres A.
    Haematologica; 2000 May 11; 85(5):530-8. PubMed ID: 10800172
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.